6-Aza-cytidin-5'-monophosphat | 2226-72-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Aza-cytidin-5'-monophosphat
• 英文别名: 4-amino-1-(O⁵-phosphono-β-D-ribofuranosyl)-1H-[1,3,5]triazin-2-one；5-Azacytidine 5'-Monophosphate 60%；[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
• CAS: 2226-72-4
• 化学式: C₈H₁₃N₄O₈P
• 分子量: 324.187
• InChiKey: WODABQYEPQRZOS-KVTDHHQDSA-N

物化性质

• 熔点：
  >127°C (dec.)
• 沸点：
  668.5±65.0 °C(Predicted)
• 密度：
  2.33±0.1 g/cm3(Predicted)
• 溶解度：
  可微溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  188
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• 5'-DIBENZYL PHOSPHATES OF 5-AZACYTIDINE OR 2'-DEOXY-5-AZACYTIDINE
  申请人：OHARA PHARMACEUTICAL CO., LTD.

  公开号：US20170152275A1

  公开（公告）日：2017-06-01

  The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R 1 and R 2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2′-deoxy-5-azacytidine) used in clinic for treating myeloma.

  本发明涉及一种新型化合物，其式表示为（1），或其盐，其中R为羟基或氢原子；R1和R2相同或不同，且分别独立地为苄基，可以具有取代基。本发明提供了治疗剂，其对胞嘧啶脱氨酶具有显著的稳定性，可以通过口服在体内被吸收，并且通过容易地被纳入体内核酸生物合成中而抑制蛋白质合成，以替代在临床上用于治疗骨髓瘤的注射剂（5-氮杂胞苷或2'-脱氧-5-氮杂胞苷）。
• 5'-POSITION DIBENZYL PHOSPHORIC ACID ESTER OF 5-AZACYTIDINE OR 2'-DEOXY BODY THEREOF
  申请人：Ohara Pharmaceutical Co., Ltd.

  公开号：EP3192799A1

  公开（公告）日：2017-07-19

  The present invention relates to a novel compound represented by formula (1), or salt thereof, wherein R is hydroxy group or hydrogen atom; R1 and R2 are the same or different, and are each independently benzyl group which may have a substituent. The present invention provides therapeutically agents, which have remarkable stability against cytidine deaminase, a metabolic enzyme, can be absorbed in vivo by oral administration and inhibit protein synthesis by being incorporated easily into nucleic acid bio-synthesis in vivo for replacing injection agent (5-azacytidine or 2'-deoxy-5-azacytidine) used in clinic for treating myeloma.

  本发明涉及一种由式（1）代表的新型化合物或其盐、 其中 R 是羟基或氢原子；R1 和 R2 相同或不同，各自独立地为苄基，可带有取代基。本发明提供的治疗剂对代谢酶胞苷脱氨酶具有显著的稳定性，可通过口服在体内吸收，并通过在体内容易结合到核酸生物合成中来抑制蛋白质合成，以取代临床上用于治疗骨髓瘤的注射剂（5-氮杂胞苷或 2'-脱氧-5-氮杂胞苷）。
• US9670238B1
  申请人：——

  公开号：US9670238B1

  公开（公告）日：2017-06-06